Literature DB >> 32359498

Fulvestrant plus capivasertib for metastatic breast cancer.

Ethan B Ludmir1, Zachary R McCaw2, Dae Hyun Kim3, Lu Tian4, Lee-Jen Wei5.   

Abstract

Entities:  

Year:  2020        PMID： 32359498     DOI： 10.1016/S1470-2045(20)30228-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.

Authors:  Fang Sun; Chenglin Mu; Hang Fai Kwok; Jiyuan Xu; Yingliang Wu; Wanhong Liu; Jean-Marc Sabatier; Cédric Annweiler; Xugang Li; Zhijian Cao; Yingqiu Xie
Journal:  Int J Biol Sci       Date:  2021-06-11       Impact factor: 6.580

Review 2.  COVID-19 challenges and its therapeutics.

Authors:  Sabi Ur Rehman; Shaheed Ur Rehman; Hye Hyun Yoo
Journal:  Biomed Pharmacother       Date:  2021-08-05       Impact factor: 6.529
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.